News
J&J IRA pricing offer is in, as it sticks with 2025 guidance...
Johnson & Johnson has three of its top-selling drugs in Medicare pricing negotiations – Stelara, Xarelto, and Imbruvica – but has said it does not expect a major hit to its finances nex
